The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Improving outcomes for FLT3-mutated R/R AML
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, talks on the treatment of patients with FLT-3 mutated relapsed/refractory (R/R) acute myeloid leukemia (AML), higlighting the use of gilteritinib as montherapy and outcomes of the Phase III ADMIRAL trial (NCT02421939). Dr Wang reports that patients who had received prior TKI therapy had poorer outcomes than patients who had not received prior TKI therapy, and comments on the need to explore combination therapies, such as gliteritinib and venetoclax, and novel FLT3 inhibitors in the upfront setting. Dr Wang also talks on resistance mechanisms to approved therapies in patients with FLT3-mutated AML. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
